Parmax Pharma Ltd

Parmax Pharma Q2 2025 Results: Revenue Drops Sharply 📉

- Revenue from operations fell to ₹19,423.11 thousand in Q2 2025, down from ₹78,163.00 thousand in Q2 2024.

- Net loss of ₹7,644.98 thousand, compared to a net profit of ₹123.20 thousand in the same quarter last year.

- Basic EPS was negative at ₹-2.04 for the quarter.

- No depreciation provided on clean room plant and effluent treatment plant due to non-usage.

- Insurance claim of ₹350 lakhs for a December 2023 fire incident remains pending.

- Mr. Samsad Alam Khan appointed as Secretarial Auditor for FY 2025-30, pending shareholder approval.

- Financial results reviewed by Audit Committee and approved by Board on August 14, 2025.

- Statutory auditors B A Shah S R Mehta & Co. conducted a limited review of results.